Allena Pharmaceuticals — Investor Presentation (October 2018)
25 slides from Allena Pharmaceuticals's investor presentation, Oct 2, 2018
Slide 1: Bringing First-in-Class Oral Enzyme Therapeutics to Patients with Rare and Severe Metabolic and Kidney Disorders
Bringing First-in-Class Oral Enzyme Therapeutics to Patients with Rare and Severe Metabolic and Kidney Disorders October 2018 Exhibit 99.1
Slide 2: Forward-Looking Statements
Allena Pharmaceuticals, Inc. These slides contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are
Slide 3: Investment Highlights
Investment Highlights Significant Unmet Need in Oxalate and Urate Disorders Late-Stage Development Candidate: Reloxaliase Pioneering Expertise in Oral Enzyme Therapeutics Focused on rare and severe metabolic disorders that can cause kidney stones, damage the kidney, and potentially lead to CKD and E
Slide 4: Allena's Pipeline: First-in-Class Therapeutic Strategy for Oxalate and Urate Disorders
Product Indication Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Next Milestone Commercial Rights Reloxaliase Enteric hyperoxaluria 2H ’18: Initiate URIROX-2 Worldwide Systemic oxalosis* 2H ’18: Interim data Worldwide Primary hyperoxaluria* (Orphan Designation) 2H ’18: Interim data Worldwide Pediat
Slide 5: Hyperoxaluria is Characterized by Markedly Elevated Urinary Oxalate Levels
Hyperoxaluria is Characterized by Markedly Elevated Urinary Oxalate Levels Source: Illustration adapted from Coe, Fred. “Control of Urine Oxalate Excretion.” Kidneystones.uchicago.edu. University of Chicago, kidneystones.uchicago.edu/control-of-urine-oxalate-excretion . March 2017. Fecal Excretion G
Slide 6: First-in-Class Therapeutic Strategy in Enzyme Therapeutics
First-in-Class Therapeutic Strategy Expertise and Proprietary Technological Approach in Enzyme Therapeutics Enables First-in-Class Therapeutic Strategy for Oxalate and Urate Disorders Reloxaliase Recombinant Protein Oral, non-absorbed, highly specific Optimized Highly Active Form of the Enzyme for G
Slide 7: No FDA approved pharmacological therapies to treat any form of hyperoxaluria
There are no FDA approved pharmacological therapies to treat any form of hyperoxaluria Enteric Hyperoxaluria (EH) Urinary Oxalate (UOx) Study 713 Patient Examples Whipple (Pancreatic Insufficiency): 14 stones in last 5 years (16 stones visible by CT) Celiac disease: 3 stones in last 2 years ( 4 ston
Slide 8: Reloxaliase Initially Targets Enteric Hyperoxaluria Patients with Underlying Malabsorptive GI Diseases
Reloxaliase Initially Targets Enteric Hyperoxaluria Patients with Underlying Malabsorptive GI Diseases and Kidney Stones 1 Truvan Health Analytics, part of the IBM Watson Health business longitudinal Claims Analysis, August 2017. Analysis tracked patients for whom an enteric disease diagnosis or pro
Slide 9: Risk of Renal Complications Rises with Higher Urinary Oxalate Levels
Risk of Renal Complications Rises with Higher Urinary Oxalate Levels: Reduction of UOx Improves Renal Outcomes Illustrative Diagram Sources: Robertson and Hughes, Scanning Microsc. 1993; Keddis Curr Opin Nephrol Hypertens. 2013; Robertson and Peacock, Nephron. 1980; Milliner, Kidney Int. 2006; Curha
Slide 10: The Patient Journey for Severe Hyperoxaluria Patients
The Patient Journey for Severe Hyperoxaluria Patients can Include Complex Specialty Care with Progressive Disease Recurrent Kidney Stones Stone Clinic Kidney Stone Disease Management Nephrologist/Urologist Metabolic Management Complex Specialty Care Monitoring Kidney Function Nephrologist Renal Dama
Slide 11: Reloxaliase for the Treatment of Hyperoxaluria
Reloxaliase for the Treatment of Hyperoxaluria
Slide 12: Clinical and Regulatory Progression of Reloxaliase
Clinical and Regulatory Progression of Reloxaliase Pre clinical Ph 1 Healthy Volunteers Ph 2 Open Label Ph 2 Randomized Controlled Ph 3 Randomized Controlled ✓ ✓ ✓ ✓ Initiate 1Q 2018 and 2H 2018 Progressive Increase in Enzyme Activity Porcine Rhubarb Model Presented at AUA 2016 Porcine Western Diet
Slide 13: Phase 3 Program Incorporates Key Learnings from Phase 2
Phase 3 Program Incorporates Key Learnings from Phase 2 Phase 3 Phase 2 Program Identified Proposed Phase 3 Patient Population Enteric population demonstrated consistent, superior, clinically and statistically significant response Identified Proposed Pivotal Endpoint Percent change from baseline to
Slide 14: Study 713: Substantially Greater Reloxaliase Treatment Response in Enteric Population
Study 713: Substantially Greater Reloxaliase Treatment Response in Enteric Population *Beyond the primary endpoint analysis, all P-values are descriptive. Enteric Reloxaliase Enteric Placebo Change in TWA Urinary Oxalate (mg/24h) Baseline Urinary Oxalate (mg/24h) Change in TWA UOx Excretion vs Basel
Slide 15: Reloxaliase Generally Well-Tolerated in Clinical Trials to Date
Reloxaliase Generally Well-Tolerated in Clinical Trials to Date 11,500 u/meal, 3,000 u/meal, and 7,500 u/meal. 2TEAE = Treatment emergent adverse events are defined as AEs with onset at the time of or following the first dose of treatment with study drug through 7 days after their last dose of study
Slide 16: Reloxaliase: Proposed Pivotal Phase 3 Program in Enteric Hyperoxaluria
1H 2017 2H 2017 1H 2018 2H 2018 1H 2019 2H 2019 1H 2020 2H 2020 1H 2021 Reloxaliase: Proposed Pivotal Phase 3 Program in Enteric Hyperoxaluria Proposed Phase 3 Program – in Discussions with the FDA, URIROX-1 Enrolling Patient Population: EH subjects with severe Hyperoxaluria (>50mg/24h), normal to m
Slide 17: URIROX-1: Safety and Efficacy of Reloxaliase in Enteric Hyperoxaluria
URIROX-1: Evaluate the Safety and Efficacy of Reloxaliase in Patients with Enteric Hyperoxaluria Key Features: Tailored dose regimen: dose with each meal/snack 3-5x per day to maximize degradation of oxalate ingested or secreted EP:Percent change from baseline in 24-h UOx excretion averaged during w
Slide 18: Regulatory Status Overview
Regulatory Status Overview: Hyperoxaluria is a High Unmet Need with No Approved Therapeutic Regulatory Challenge Opportunities Enteric Hyperoxaluria is a rare disease with a high burden of kidney stones and kidney damage High unmet need due to inadequate existing therapies With no approved drugs: No
Slide 19: Reloxaliase Additional Indications
Reloxaliase Additional Indications
Slide 20: Elevated Plasma Oxalate Increases Risk for CaOx Crystal Deposition
Elevated Plasma Oxalate Increases Risk for CaOx Crystal Deposition in the Kidney and Other Organ Systems Time and progression of disease Plasma Oxalate Level CKD 1 CKD 2 CKD 3 CKD 4 ESRD 0 15 30 45 2-5 µmol/L Normal range Systemic Oxalosis Dialysis Hyperoxalemia Study Population: Enteric Hyperoxalur
Slide 21: Reloxaliase Potential to Reduce Oxalate Burden in Primary and Enteric Hyperoxaluria with Advanced CKD
Reloxaliase has the Potential to Reduce Oxalate Burden in Patients with Primary Hyperoxaluria and Enteric Hyperoxaluria with Advanced CKD Sources: Grujic et al, Am. J Nephrol 2009; 29: 86-93 and company data *Pigs not colonized with oxalobacter formigenes. Degraded Oxalate in the GI Tract and Reduce
Slide 22: Study 206: Reloxaliase in Primary or Enteric Hyperoxaluria and Advanced CKD
Screening and Baseline 28 d Follow up 4 Weeks Study 206: Reloxaliase Treatment of Adult and Pediatric Patients with Primary or Enteric Hyperoxaluria and Advanced CKD ('Basket' Study) Primary Hyperoxaluria (PH) Enteric Hyperoxaluria (EH) Urinary Oxalate (UOx) Plasma Oxalate (POx) Regulatory: Reloxali
Slide 23: ALLN-346: Significant Opportunity in Gout Patients with Moderate-to-Severe CKD
ALLN-346: Significant Opportunity in Gout Patients with Moderate-to-Severe CKD The Gout Market is Incompletely Served by Existing Therapies ~375,000 gout patients with moderate to severe CKD who have uncontrolled gout on urate lowering therapy (ULT) Gout patients with renal impairment are not well m
Slide 24: Clinical and Regulatory Milestones
Clinical and Regulatory Milestones YEAR TARGET MILESTONE STATUS (October 2018) 2017 4Q17 Initiate ALLN-346 Animal Studies ü 2018 1Q18 Initiate Study 301 ü 1Q18 Initiate Study 206, Phase 2 Study in PH and EH with Hyperoxalemia ü 2H18 Initiate Study 302 On Track 2H18 Study 206 Interim Data On Track 20
Slide 25: Investment Highlights
Investment Highlights Significant Unmet Need in Oxalate and Urate Disorders Late-Stage Development Candidate: Reloxaliase Pioneering Expertise in Oral Enzyme Therapeutics Focused on rare and severe metabolic disorders that can cause kidney stones, damage the kidney, and potentially lead to CKD and E
Allena Pharmaceuticals — Investor Presentation (October 2018) on 6ix